COGSTATE LIMITED (CGS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CGS

CGS - COGSTATE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.03
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.70

01 Sep
2025

-0.010

OPEN

$1.70

-0.58%

HIGH

$1.73

107,947

LOW

$1.68

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx9.2
DPS All xxxxxxxxxxxxxxx2.0
Sales/Revenue xxxxxxxxxxxxxxx82.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.3
Net Operating Cash Flow xxxxxxxxxxxxxxx19.0 M
Net Profit Margin xxxxxxxxxxxxxxx19.11 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx23.32 %
Return on Invested Capital xxxxxxxxxxxxxxx23.11 %
Return on Assets xxxxxxxxxxxxxxx16.89 %
Return on Equity xxxxxxxxxxxxxxx23.32 %
Return on Total Capital xxxxxxxxxxxxxxx29.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx18.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx54 M
Price To Book Value xxxxxxxxxxxxxxx4.03

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx5.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

27/08/2025

1

Buy

$2.19

28.82%

Canaccord Genuity notes Cogstate's FY25 revenue of US$53.1m came in line with guidance and its forecast. The highlight were very strong new contract executions of US$40.1m and FY26 to-date also impressed at US$14.1m.

The broker suggests a shift towards multiple smaller contracts across broader indications (schizophrenia, bipolar, depression, Alzheimer’s) rather than one-off large deals improves revenue visibility and sustainability.

The company guided to revenue growth in FY26 but didn't quantify. The broker sees -300bp impact on EBITDA from spending to support new contracts and investments, but expects longer-term EBITDA margin at 30%.

Buy. Target lifted to $2.19 from $1.85.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 1.71 cents and EPS of 8.68 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 2.94 cents and EPS of 10.07 cents.
Access Extra Coverage Research History >

CGS STOCK CHART

FNArena News on CGS

1
Australian Broker Call *Extra* Edition – Aug 27, 2025

Aug 27 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Aug 12, 2025

Aug 12 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jun 05, 2025

Jun 05 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jan 23, 2025

Jan 23 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 28, 2024

Aug 28 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia